Literature DB >> 6378699

The effects of biosynthetic human proinsulin on carbohydrate metabolism.

R R Revers, R Henry, L Schmeiser, O Kolterman, R Cohen, R Bergenstal, K Polonsky, J Jaspan, A Rubenstein, B Frank.   

Abstract

Large quantities of biosynthetic human proinsulin have recently become available through recombinant DNA technology. Since the in vivo effects of human proinsulin have not been studied in man, we compared the dose-response relationship for stimulation of glucose disposal and suppression of hepatic glucose output by proinsulin and insulin. Ten normal subjects were studied using the euglycemic glucose clamp technique. The human proinsulin and insulin infusion rates were chosen to achieve steady-state proinsulin levels 10-fold higher than insulin levels on a molar basis, based on previous observations that porcine proinsulin has approximately 10% the potency of insulin. Proinsulin infusion rates of 2.75, 7.5, 22.5, and 45 micrograms/m2/min were compared with insulin infusion rates of 0.63, 1.67, 5, and 10 micrograms/m2/min. Primed, continuous infusions of insulin yielded steady-state levels within 25 min, whereas proinsulin levels did not reach a steady state for 120-180 min. The metabolic clearance rate of insulin was 11-12 ml/kg/min at the lower infusion rates but fell to 8.4 ml/kg/min at the highest infusion rate. The metabolic clearance rate of proinsulin was 3.0-3.5 ml/kg/min at all infusion rates. Dose-response analysis demonstrated that proinsulin-mediated glucose disposal was approximately 8% that of insulin. In contrast, proinsulin-mediated suppression of hepatic glucose output was approximately 12% that seen with insulin.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378699     DOI: 10.2337/diab.33.8.762

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  16 in total

1.  In vivo stimulation of the insulin receptor kinase in human skeletal muscle. Correlation with insulin-stimulated glucose disposal during euglycemic clamp studies.

Authors:  G R Freidenberg; S L Suter; R R Henry; D Reichart; J M Olefsky
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

2.  Receptor-mediated activation of a proinsulin-transferrin fusion protein in hepatoma cells.

Authors:  Yan Wang; Yu-Sheng Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  J Control Release       Date:  2011-07-02       Impact factor: 9.776

3.  Conversion of biosynthetic human proinsulin to partially cleaved intermediates by collagenase proteinases adsorbed to isolated rat adipocytes.

Authors:  W C Duckworth; D E Peavy; F G Hamel; J Liepnieks; M R Brunner; R E Heiney; B H Frank
Journal:  Biochem J       Date:  1988-10-01       Impact factor: 3.857

4.  Different binding and degradation of proinsulin, insulin and insulin-like growth factor-1 (IGF-1) in cultured renal proximal tubular cells. Implications for the prolonged serum half-life of proinsulin.

Authors:  P M Jehle; R D Fussgänger; S Stracke; R W Grunewald; F Keller
Journal:  Acta Diabetol       Date:  1996-07       Impact factor: 4.280

5.  Assessment of proinsulin's effects on intermediary metabolism using the forearm technique in normal man.

Authors:  S N Davis; L Monti; P M Piatti; M Ansiferov; C Hetherington; M Brown; H Orskov; W Branch; C N Hales; K G Alberti
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

6.  Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects.

Authors:  P M Clark; J C Levy; L Cox; M Burnett; R C Turner; C N Hales
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

7.  Metabolism and placental transfer of 125I-proinsulin and 125I-tyrosylated C-peptide in the pregnant rhesus monkey.

Authors:  P A Gruppuso; J B Susa; P Sehgal; B Frank; R Schwartz
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

8.  Biochemical and clinical implications of proinsulin conversion intermediates.

Authors:  B D Given; R M Cohen; S E Shoelson; B H Frank; A H Rubenstein; H S Tager
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Scintigraphic distribution of 123 I labelled proinsulin, split conversion intermediates and insulin in rats.

Authors:  F Sodoyez-Goffaux; J C Sodoyez; M Koch; C J De Vos; B H Frank
Journal:  Diabetologia       Date:  1988-11       Impact factor: 10.122

10.  Endocytotic uptake, processing, and retroendocytosis of human biosynthetic proinsulin by rat fibroblasts transfected with the human insulin receptor gene.

Authors:  J R Levy; A Ullrich; J M Olefsky
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.